A Lifeline for Low-Income Patients at Risk? That's the alarming claim from Oregon Health & Science University (OHSU) President Dr. Shereef Elnahal, who's sounding the alarm about a new drug discount program piloted under the Trump administration. But here's where it gets controversial: this program, designed to help hospitals serving low-income patients, might actually jeopardize their ability to provide care.
Let’s break it down. The 340B Drug Discount Program, established in the 1990s, has been a lifeline for hospitals and clinics treating large numbers of uninsured, Medicaid, or low-income patients. It allows these safety-net providers to purchase certain outpatient medications at steeply discounted prices—often half or less than the usual cost—while billing insurers at full price. The savings are then used to fund free or reduced-cost care for those in need.
However, the new 340B Rebate Model Pilot Program, set to begin next year, flips this model on its head. Instead of receiving discounted prices upfront, hospitals and clinics would pay the full list price for medications and apply for a rebate later. This means they’d have to front the cost and wait for repayment—a significant cash-flow challenge, especially for institutions like OHSU that serve a high volume of vulnerable patients.
And this is the part most people miss: The pilot program, while voluntary for drugmakers, applies only to nine of the most expensive Medicare-covered drugs, including Jardiance, Enbrel, and Eliquis. These are medications that many low-income patients rely on, and the financial strain of paying full price upfront could force hospitals to make tough choices about the care they provide.
Federal officials argue that the pilot aims to test whether a rebate system can be implemented fairly and transparently, addressing concerns from both hospitals and drug manufacturers. But critics, including Dr. Elnahal, worry that the program could disrupt the very safety net it’s meant to support.
Adding to the complexity, hospitals participating in the pilot would face new administrative burdens. To receive rebates, they must submit detailed data to manufacturers within 45 days of dispensing a drug, with drugmakers then having 10 days to issue payments. This additional paperwork could further strain already overburdened healthcare systems.
The 340B program has been a critical revenue stream for OHSU, generating $480 million in the fiscal year ending June 2025—a $137 million increase from the previous year. Yet, the program has also faced scrutiny. Critics, including drugmakers and some members of Congress, argue that it has grown far beyond its original intent, with large hospital systems profiting without always demonstrating clear benefits to patients.
Participation in the program has surged in recent years, with over 50 of Oregon’s 61 hospitals and more than 30 federally qualified health centers enrolled. Nationwide, more than half of nonprofit hospitals now participate. Drug purchases through 340B skyrocketed from $12 billion in 2015 to $66 billion in 2023, according to federal data.
Supporters counter that this growth reflects broader changes in healthcare, such as increased Medicaid enrollment following the Affordable Care Act and hospitals expanding into underserved areas. However, studies have shown that the program’s expansion has contributed to higher healthcare costs for employers, government programs, and taxpayers, sparking calls for greater oversight and transparency.
Here’s the burning question: Is the 340B Rebate Model Pilot Program a step toward fairness and accountability, or does it risk undermining the very safety net it’s meant to strengthen? Dr. Elnahal’s concerns highlight the delicate balance between fiscal responsibility and patient care.
What do you think? Is this pilot program a necessary reform, or a misguided experiment that could harm vulnerable patients? Share your thoughts in the comments—this is a conversation that needs your voice.
